Login / Signup

Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database.

Young-Jin KoSeonji KimKyounghoon ParkMinsuk KimBo Ram YangJoongyub LeeMi-Sook KimByung-Joo Park
Published in: Therapeutic advances in drug safety (2019)
Rivaroxaban might have stronger association with bleeding than apixaban and dabigatran.
Keyphrases
  • atrial fibrillation
  • oral anticoagulants
  • adverse drug
  • human health
  • venous thromboembolism
  • emergency department
  • electronic health record
  • climate change
  • risk assessment